GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
Are molecular markers just for NSCLC?
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM ...
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.
-
HD
Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. David Spigel gives his view on more widespread availability ...
Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.
-
HD
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"
Dr. Heather Wakelee, from Stanford University, describes which molecular markers ...
Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.
-
HD
Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 ...
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
-
HD
Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Dr. Mary Pinder reviews promising studies from ASCO 2013 on ...
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
-
HD
Can we harness our immune system to fight NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising ...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.
-
HD
Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the ...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
-
HD
Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ ...
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
-
HD
Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Karen Kelly, of the University of California, Davis, gives ...
Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.
-
HD
Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West review the ...
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
